亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Treatment of liver cirrhosis using hepatocyte-derived liver progenitor-like cells: a prospective, open-label, single-arm, safety trial

医学 肝硬化 不利影响 临床试验 肝移植 内科学 胃肠病学 旁分泌信号 毒性 肝病 移植 肝功能 临床意义 体内分布 随机对照试验 肝细胞 基质金属蛋白酶 外科 间隙 动物研究 药理学
作者
Kang He,Xuejing Zhu,Yao-Ping Shi,Weijian Huang,Taihua Yang,Zhifeng Xi,Qigen Li,Hanyong Sun,Lijun Qian,Xiaosong Chen,Peiying Li,Xu Zhou,Guiying Gu,Fan Li,Wenming Liu,Cai–Yang Chen,Jie Zhao,Hongping Wu,Fangrong Yan,Michael Ott
出处
期刊:Cell discovery [Springer Nature]
卷期号:11 (1): 88-88 被引量:9
标识
DOI:10.1038/s41421-025-00831-y
摘要

Liver transplantation remains constrained by the scarcity of donor organs and the risks inherent in the procedure, underscoring the urgent need for novel cirrhosis therapies. We developed a protocol to convert human primary hepatocytes into expandable hepatocyte-derived liver progenitor-like cells (HepLPCs), which secrete high levels of matrix metalloproteinases and hepatocyte growth factor. In a thioacetamide-induced rat model of cirrhosis, human HepLPCs demonstrated potent anti-fibrotic properties and promoted liver regeneration. Biodistribution studies revealed that most xenogenic HepLPCs were cleared from the body within one week, suggesting that their therapeutic benefits likely arise from paracrine signaling rather than long-term engraftment. We initiated a first-in-human clinical trial involving nine patients with cirrhosis to evaluate the feasibility and safety of HepLPCs. Preclinical toxicity assessments in 36 crab-eating macaques confirmed the safety of HepLPC treatment. In the clinical trial, nine patients (mean age: 53 years), primarily with HBV-related cirrhosis, received HepLPCs via trans-hepatic arterial infusion without immunosuppressants. No serious adverse event was observed, and the minor adverse events were consistent with those commonly seen in cirrhosis patients. The treatment was well tolerated, with no transfusion reactions or dose-limiting toxicities. While significant changes in Child-Pugh and MELD scores were not observed, some patients showed improvements in liver biochemical parameters, coagulation profiles, and portal hypertension indicators during the six-month follow-up. These findings indicate that HepLPC therapy is safe and feasible, offering a promising new strategy for treating cirrhosis. Further clinical trials are needed to assess its efficacy in patients with decompensated cirrhosis and acute-on-chronic liver failure.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
大模型的应助被lmn采纳,获得10
1秒前
3秒前
感性的雅霜完成签到,获得积分10
3秒前
4秒前
Kaikai发布了新的文献求助10
7秒前
8秒前
mmyhn发布了新的文献求助10
8秒前
9秒前
星辰大海的应助被Lia_Yee采纳,获得10
14秒前
18秒前
Jeff发布了新的文献求助20
21秒前
Jeff发布了新的文献求助50
21秒前
21秒前
狂野羿完成签到,获得积分10
24秒前
水逆消退发布了新的文献求助10
26秒前
fangzhi完成签到,获得积分10
27秒前
zwhy579完成签到 ,获得积分10
28秒前
mmyhn发布了新的文献求助10
29秒前
31秒前
易安完成签到 ,获得积分10
32秒前
Owen的应助被虚心的灵寒采纳,获得80
33秒前
重要白亦发布了新的文献求助10
35秒前
Zz完成签到,获得积分10
42秒前
42秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
45秒前
fantasy的应助被科研通管家采纳,获得10
45秒前
45秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
46秒前
46秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
46秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
46秒前
星辰完成签到,获得积分10
46秒前
领导范儿的应助被科研通管家采纳,获得10
46秒前
YQY发布了新的文献求助10
46秒前
lmn发布了新的文献求助10
48秒前
48秒前
TIMF14完成签到,获得积分10
48秒前
慕青的应助被我我我采纳,获得30
49秒前
51秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172954
求助须知:如何正确求助?哪些是违规求助? 9565447
关于积分的说明 21780029
捐赠科研通 7764817
什么是DOI,文献DOI怎么找? 3431496
关于科研通互助平台的介绍 2555519
邀请新用户注册赠送积分活动 2476571